Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Phase 1

Recruiting

Conditions: Bladder Cancer
Advanced Malignancies
Head and Neck Squamous Cell Carcinoma (HNSCC)
Advanced Cancer
Esophageal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer (NSCLC)
Ovarian Cancer
Renal Cell Carcinoma (RCC)
Triple Negative Breast Cancer (TNBC)

Interventions: Drug: AB598
Drug: Zimberelimab
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2023-06-06

Last Posted Date: 2024-12-05

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 87

Registration Number: NCT05891171

Locations: 🇺🇸
Mayo Arizona, Phoenix, Arizona, United States
🇺🇸
Mayo Florida, Jacksonville, Florida, United States
🇺🇸
Affinity Health Hope and Healing Cancer Services, LLC, Hinsdale, Illinois, United States

and more 11 locations

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3

Recruiting

Conditions: Metastatic Colorectal Carcinoma
Metastatic Malignant Neoplasm in the Liver
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma

Interventions: Biological: Cetuximab
Biological: Bevacizumab
Procedure: Computed Tomography
Drug: Floxuridine
Drug: Fluorouracil
Procedure: Implantation
Drug: Irinotecan
Procedure: Intrahepatic Infusion Procedure
Drug: Leucovorin
Drug: Oxaliplatin
Biological: Panitumumab
Procedure: Single Photon Emission Computed Tomography

First Posted Date: 2023-05-17

Last Posted Date: 2024-11-05

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 408

Registration Number: NCT05863195

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States

and more 36 locations

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

Phase 2

Recruiting

Conditions: Oral Squamous Cell Carcinoma

Interventions: Drug: Tislelizumab
Drug: Albumin paclitaxel
Drug: Cisplatin
Drug: 5-Fluorouracil

First Posted Date: 2023-05-17

Last Posted Date: 2023-07-17

Lead Sponsor: Weijia Fang, MD

Target Recruit Count: 30

Registration Number: NCT05862168

Locations: 🇨🇳
First affiliated hospital, School of Medicine, Zhejiang University, Hangzhou, China

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Hydroxychloroquine
Drug: Irinotecan
Drug: Fluorouracil
Drug: Leucovorin
Drug: Bevacizumab

First Posted Date: 2023-05-06

Last Posted Date: 2024-02-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 155

Registration Number: NCT05843188

Locations: 🇨🇦
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients

Phase 1

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: AK119
Drug: AK112
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Calcium folinate
Drug: Fluorouracil

First Posted Date: 2023-05-06

Last Posted Date: 2023-05-06

Lead Sponsor: Akeso

Target Recruit Count: 72

Registration Number: NCT05846867

Locations: 🇨🇳
Cancer Hospital Affiliated to Harbin Medical University, Harbin, China

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: cadonilimab
Drug: irinotecan
Drug: Oxaliplatin
Drug: leucovorin or levoleucovorin
Drug: 5-FU

First Posted Date: 2023-05-03

Last Posted Date: 2023-11-15

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05839470

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Adaptive Radiation in Anal Cancer

Not Applicable

Recruiting

Conditions: Anal Squamous Cell Carcinoma

Interventions: Radiation: Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery
Drug: Mitomycin-C
Drug: 5-Fluorouracil
Drug: Capecitabine

First Posted Date: 2023-05-01

Last Posted Date: 2024-07-11

Lead Sponsor: Columbia University

Target Recruit Count: 20

Registration Number: NCT05838391

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2

Active, not recruiting

Conditions: Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Drug: Capecitabine
Procedure: Computed Tomography
Drug: Docetaxel
Procedure: Echocardiography
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Lymphadenectomy
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography
Procedure: Surgical Procedure

First Posted Date: 2023-05-01

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 240

Registration Number: NCT05836584

Locations: 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Kaiser Permanente Dublin, Dublin, California, United States

and more 133 locations